Sign up to hear about how you can be part of exciting future events like melACTION
This link will take you to an MSD website to give your consent to receive marketing and promotional emails from MSD about our products, services and events.
An Oncologist and Surgeon discuss: The adjuvant melanoma patient pathway
An Oncologist and Surgeon discuss: The adjuvant melanoma patient pathway
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
The 5 minute video below shows highlights from the ‘An Oncologist and Surgeon discuss: The adjuvant melanoma patient pathway’ session at our educational melanoma meeting ‘melACTION’, in 2023. Dr Ricky Frazer and Mr Jonathan Pollock, representing their respective disciplines of Oncology and Plastic Surgery explore the complex patient pathway in melanoma and how MDT collaboration can improve the patient experience with regard to adjuvant therapy.
KEYTRUDA as monotherapy is indicated for:1
- The treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma
- The adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC or III melanoma and who have undergone complete resection
Click to download the melACTION highlights report, including:
- Full agenda
- Session summaries
- Attendee highlights
References
- KEYTRUDA Summary of Product Characteristics.
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
